Arkrivis Technologies has announced that it was awarded by the National Cancer Institute (NCI) its second Phase I SBIR Contract.
Akrivis will collaborate with Washington University School of Medicine, in St. Louis, to develop its proprietary ADAPT™ technology platform for pre-targeted radiotherapy aimed at Acute Myeloid Leukemia (AML).
Leave a Comment